Brazil, India and South Africa call for flexibility on compulsory drug licensing
Brazil, India and South Africa joined forces to reject pressure for the extension of intellectual property rights and called for effective use of flexibilities such as compulsory licensing.
The position was manifested during a seminar promoted by these three countries for the international community. The seminar also addressed “legal confusion” between generic and counterfeit drugs, reports the Brazilian pharma trade group ABINIFA.
Brazilian Ambassador Maria Nazareth Farani Azevedo explained that "counterfeit drugs are a serious problem. Nobody is here to promote the sale of counterfeit or to promote the sale of any medication to the detriment of the human right to health".
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze